Posted: Fri Oct 09, 2009 5:03 am Post subject: GSK and Kaketsuken Will Co-Develop EB66 Cell Based Flu Vax
The agreement aims to integrate cell-culture technology and know-how owned by or licensed to GSK and Kaketsuken (including the EB66(R) cell line in-licensed by GSK from Vivalis) with GSK's adjuvant technology in order to co-develop, manufacture and supply a cell-culture based pandemic influenza vaccine as early as possible in Japan.
With this collaboration, GSK and Kaketsuken are committed to contributing to Japan's pandemic plan through developing and making available as quickly as possible a cell-culture based pandemic influenza vaccine to as many people as possible in need of this vaccine.
Kaketsuken has been fulfilling its responsibilities of supplying seasonal influenza vaccines in Japan over the years and as a part of the country's pandemic response plan, it is manufacturing pandemic vaccine solutions for H5N1, contributing to the government's stockpiling. It is also currently manufacturing vaccines for the swine-derived H1N1 influenza that continues to spread.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum